Analysis of Adverse Reactions Caused by Potentially Inappropriate Prescriptions and Related Medical Costs That Are Avoidable Using the Beers Criteria: The Japanese Version and Guidelines for Medical Treatment and Its Safety in the Elderly 2015
Analysis of Adverse Reactions Caused by Potentially Inappropriate Prescriptions and Related Medical Costs That Are Avoidable Using the Beers Criteria: The Japanese Version and Guidelines for Medical Treatment and Its Safety in the Elderly 2015
复制标题
DOI：
10.1248/bpb.b18-00820
复制
发表时间：
2019-05-01
影响因子：
2
通讯作者：
Teramachi, Hitomi
中科院分区：
文献类型：
--
作者：
Tachi, Tomoya;Kanematsu, Yuta;Teramachi, Hitomi
我们进行了一项回顾性研究，旨在调查老年人的药物不良反应和相关医疗费用，如果按照 Beers 标准：日本版 (BCJV) 和 2015 年老年人医疗及其安全指南 (GL2015) 进行药物治疗，这些不良反应和相关医疗费用是可以避免的。研究纳入了2014年10月1日至11月30日期间在岐阜市立医院住院的65岁以上患者（n = 1236）或2014年10月1日至2日在岐阜市立医院门诊检查的患者（n = 980）。测量的结果是 BCJV 和 GL2015 中列出的药物的使用率、药物不良反应的发生率以及每个患者因不良反应而产生的额外费用。住院患者中，BCJV和GL2015所列药物的使用率分别为24.0%和72.4%，不良反应发生率分别为3.0%和8.2%。门诊患者中，使用率分别为26.2%（BCJV）和59.9%（GL2015），不良反应发生率分别为4.7%（BCJV）和3.9%（GL2015）。每位患者因药品不良反应而产生的额外费用为12713-163925日元不等。我们的结果表明，适当使用基于 BCJV 和 GL2015 的药物有助于预防不良反应；这将减少总体医疗费用。
We conducted a retrospective study to investigate adverse drug reactions and associated medical costs among elderly individuals that could be avoided if pharmacotherapy was performed in accordance with the Beers Criteria: the Japanese Version (BCJV) and Guidelines for Medical Treatment and Its Safety in the Elderly 2015 (GL2015). Patients aged at least 65 years who were either hospitalized at Gifu Municipal Hospital between October 1 and November 30, 2014 (n = 1236) or had outpatient examinations at Gifu Municipal Hospital on October 1-2, 2014 (n = 980) were included in the study. The outcomes measured were usage rates of drugs listed in the BCJV and GL2015, incidence rates of adverse drug reactions, and additional costs incurred per patient due to adverse reactions. Among the inpatients, usage rates of drugs listed in the BCJV and GL2015 were 24.0 and 72.4%, respectively, and adverse reactions to these drugs occurred at rates of 3.0 and 8.2%, respectively. Among the outpatients, while the usage rates were 26.2% (BCJV) and 59.9% (GL2015), the incidence rates of adverse reactions were 4.7% (BCJV) and 3.9% (GL2015). The additional costs incurred due to adverse drug reactions ranged from 12713-163925 yen per patient. Our results demonstrate that appropriate use of drugs based on the BCJV and GL2015 can help prevent adverse reactions; this would reduce the overall medical costs.